Literature DB >> 31833556

Transcription Factor Enrichment Analysis in Enhancers Identifies EZH2 as a Susceptibility Gene for Osteoporosis.

Meng Li1, Shi Yao2, Yuan-Yuan Duan2, Yu-Jie Zhang2, Yan Guo2, Hui-Min Niu2, Shan-Shan Dong2, Yu-Sheng Qiu1, Tie-Lin Yang2.   

Abstract

PURPOSE: Genome-wide association studies (GWASs) have identified hundreds of single nucleotide polymorphisms (SNPs) associated with osteoporosis. Most of these SNPs are noncoding variants and could be mapped to enhancers. Transcription factors (TFs) play important roles in gene regulation via enhancers harboring these SNPs; thus, we aimed to identify common regulatory TFs binding to enhancers associated with osteoporosis.
METHODS: We first annotated all the osteoporosis-related SNPs identified by GWASs to enhancers and conducted TF enrichment analyses to identify common TFs binding to osteoporosis-associated enhancers. We further conducted genetic association analyses between the identified TFs and bone mineral density (BMD) in a Han Chinese population.
RESULTS: After functional annotation, a total of 5081 osteoporosis-related SNPs were mapped to enhancers. TF enrichment analyses identified 2 significant TFs after multiple testing adjustments, which are EZH2 (Padj = .028) and NRSF (Padj = .038). We also found 1 SNP, rs111851041, in EZH2 was significantly associated with BMD both at the hip and spine after multiple testing adjustments (hip BMD: P = 4.32 × 10-4; spine BMD: P = 2.72 × 10-3). The expression of EZH2 decreased significantly from 12 to 48 hours of osteogenic differentiation. And functional validation showed that EZH2 was associated with osteoporosis-related phenotypes in knockout mice.
CONCLUSIONS: By conducting TF enrichment analyses, we identified EZH2 as a common TF binding to osteoporosis-associated enhancers, and EZH2 was also associated with BMD in a Chinese population. EZH2 is functionally related to bone phenotypes. The identified gene could provide new insight into osteoporosis pathophysiology and highlight opportunities for future clinical and pharmacological research on osteoporosis. © Endocrine Society 2019. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  EZH2; SNP; enhancer; osteoporosis; transcription factor

Mesh:

Substances:

Year:  2020        PMID: 31833556     DOI: 10.1210/clinem/dgz270

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  1 in total

Review 1.  Perspective of the GEMSTONE Consortium on Current and Future Approaches to Functional Validation for Skeletal Genetic Disease Using Cellular, Molecular and Animal-Modeling Techniques.

Authors:  Martina Rauner; Ines Foessl; Melissa M Formosa; Erika Kague; Vid Prijatelj; Nerea Alonso Lopez; Bodhisattwa Banerjee; Dylan Bergen; Björn Busse; Ângelo Calado; Eleni Douni; Yankel Gabet; Natalia García Giralt; Daniel Grinberg; Nika M Lovsin; Xavier Nogues Solan; Barbara Ostanek; Nathan J Pavlos; Fernando Rivadeneira; Ivan Soldatovic; Jeroen van de Peppel; Bram van der Eerden; Wim van Hul; Susanna Balcells; Janja Marc; Sjur Reppe; Kent Søe; David Karasik
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-30       Impact factor: 5.555

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.